Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/6090
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKonkle, Barbara A.-
dc.contributor.authorOldenburg, Johannes-
dc.contributor.authorPasi, John-
dc.contributor.authorKulkarni, Roshni-
dc.contributor.authorNolan, Beatrice-
dc.contributor.authorMahlangu, Johnny-
dc.contributor.authorYoung, Guy-
dc.contributor.authorBrown, Simon A.-
dc.contributor.authorPabinger, Ingrid-
dc.contributor.authorShapiro, Amy-
dc.contributor.authorNégrier, Claude-
dc.contributor.authorBlanchette, Victor-
dc.contributor.authorRagni, Margaret V.-
dc.contributor.authorDumont, Jennifer-
dc.contributor.authorLethagen, Stefan-
dc.date.accessioned2024-06-20T00:30:17Z-
dc.date.available2024-06-20T00:30:17Z-
dc.date.issued2023-
dc.identifier.citationResearch and practice in thrombosis and haemostasis, 2023 (7) 6 p.102180en
dc.identifier.urihttps://dora.health.qld.gov.au/qldresearchjspui/handle/1/6090-
dc.description.abstractBackground: Recurrent joint bleeds are a major cause of morbidity in severe hemophilia. Prophylaxis with efmoroctocog alfa (a recombinant factor VIII Fc fusion protein, [rFVIIIFc]) has demonstrated benefits beyond bleed control, including joint health maintenance.; Objectives: To assess long-term efficacy and safety of rFVIIIFc prophylaxis in severe hemophilia A in phase 3 pivotal (A-LONG/Kids A-LONG) and extension (ASPIRE) studies.; Methods: Longitudinal analysis included pooled data from A-LONG/Kids A-LONG and ASPIRE. Subgroup analyses investigated outcomes in modified Hemophilia Joint Health Score or Hemophilia Joint Health Score and target joints in subjects with 4 to 5 years follow-up on individualized prophylaxis (IP), and those with the highest annualized bleeding rate (ABR) quartile during Year 1 of IP.; Results: Overall, rFVIIIFc consumption remained stable and low ABRs were maintained, with a median treatment duration of 4.2/3.4 years in subjects from A-LONG/Kids A-LONG, respectively. Median overall ABR also remained low (1.0-2.0) in subjects on IP for 4 to 5 years. Sustained improvements in modified Hemophilia Joint Health Score or Hemophilia Joint Health Score were demonstrated over a median follow-up of 3.7 years. In subjects from A-LONG/Kids A-LONG, 99.6% ( n  = 234)/100% ( n  = 9) of evaluable baseline target joints were resolved, with no recurrence in 95%/100% of target joints. In IP subjects within the highest ABR quartile in Year 1, continued improvements were observed over a median follow-up of 4.3 years in ABR and joint health, without increased factor consumption. No inhibitors or treatment-related serious adverse events were reported.; Conclusion: Previously treated subjects of all ages receiving long-term prophylaxis with rFVIIIFc had sustained clinical benefits, including improved joint health and low ABR. (© 2023 The Author(s).)-
dc.titleProphylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults-
dc.identifier.doi10.1016/j.rpth.2023.102180-
dc.relation.urlhttps://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,athens&db=mdc&AN=37753224&site=ehost-live-
dc.identifier.journaltitleResearch and practice in thrombosis and haemostasis-
dc.identifier.risid4193-
dc.description.pages102180-
dc.description.volume7-
dc.description.issue6-
item.fulltextNo Fulltext-
item.grantfulltextnone-
Appears in Sites:Children's Health Queensland Publications
Show simple item record

Page view(s)

8
checked on Nov 22, 2024

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.